Skip to main content
OpenTrials
Completed

NCT Number: NCT01859455

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Novartis Investigative Site, Fort Myers, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good health with fasting LDL-cholesterol >90 mg/dL and fasting serum triglycerides <400 mg/dL
  • Patients on statin therapy: Male and female patients 18 to 70 years of age receiving atorvastatin or simvastatin and with fasting LDL-cholesterol >90 mg/dL and fasting serum triglycerides <400 mg/dL

Exclusion criteria

Healthy volunteers:

  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
  • Women of child-bearing potential unless using highly effective methods of contraception
  • Conditions which might impact the safety or biologic activity of the study drug

Statin patients:

  • Use of concomitant medications known to impact the safe use or efficacy of atorvastatin and simvastatin based on drug labels
  • Women of childbearing potential unless using highly effective methods of contraception during dosing and for at least 100 days after study drug administration
  • Conditions which might impact the safety or biologic activity of the study drug

Other protocol-defined inclusion/exclusion criteria may apply.

Treatment and study plan

LGT209 50 mg

Drug

Active experimental drug

LGT209 300 mg

Drug

Active experimental drug

Placebo

Drug

Placebo comparator

Statins (atorvastatin or simvastatin)

Drug

Stable doses of atorvastatin or simvastatin

Other names: Atorvastatin, Simvastatin

Primary outcomes

  1. Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death

    Time frame: 12 weeks

  2. Plasma concentrations of LGT209 following subcutaneous administration

    Time frame: 12 weeks

  3. Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration

    Time frame: baseline and 12 weeks

  4. Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration

    Time frame: baseline and 12 weeks

Secondary outcomes

  1. Plasma concentrations of atorvastatin in patients

    Time frame: 2 weeks

  2. Plasma concentrations of simvastatin in patients

    Time frame: 2 weeks

  3. Serum concentrations of PCSK9

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
May 22, 2013
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.